EMA Recommends Ryjunea for Pediatric Myopia

An eye drop formulation intended to slow progression of myopia in children has been recommended for a marketing authorization by the European Medicines Agency (EMA). Ryjunea, developed by Santen Oy, was submitted under a hybrid application. This process allows partial reliance on preclinical tests and clinical trials of an already-authorized reference product…